SYGNIS AG announces management changes
David Roth appointed Chief Financial Officer (CFO)
Pilar de la Huerta continues to serve as Co-CEO and is appointed Chief Business Development Officer (CBDO)
SYGNIS realigns its management to further accelerate growth
SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that the Supervisory Board has resolved important changes and additions to the senior management team to better align the organisational structure with the strategic goals of the Company in terms of corporate growth.
The Supervisory Board has appointed Daniel Roth as the new Chief Financial Officer of the Company, with effect from 1 March 2017. Pilar de la Huerta continues to contribute her expertise to the Company, remaining Co-CEO together with Dr. Heikki Lanckriet, and additionally assuming a new role as the Company’s Chief Business Development Officer (CBDO).
David Roth, a native German living in the UK, has over 20 years financial management experience with a special focus on the healthcare sector. He is a chartered accountant having worked with KPMG, Deloitte and Arthur Andersen in the UK where he became a director and partner within the audit and advisory practice. Here he acted for a wide range of clients, including biotech companies as well as advising listed companies both in the UK and the US. More recently, he acted as CFO of several international organisations, all of them high-growth healthcare businesses, leading financial and operational teams. His responsibilities included a $100m secondary NASDAQ listing and subsequent reporting roles, as well as analysis and financial support in several business acquisitions and corporate transactions. In his role as Chief Financial Officer at SYGNIS he will be in charge of the financial strategy and accounting processes.
Dr. Cristina Garmendia Mendizábal, Chairwoman of SYGNIS' Supervisory Board, said: "We welcome David to SYGNIS as an ideal addition to the management team. We are convinced that his experience in business acquisitions and corporate transactions will contribute significantly to the successful development of SYGNIS. It is also a great advantage to have a colleague with a German background and with in-depth knowledge of the German market in the management team. With Heikki’s expertise in sales, marketing and operations as well as his deep scientific knowledge plus Pilar's excellent network in the international investor and business community, the extended executive team will help advance the execution of SYGNIS’ growth strategy and success."
This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.
SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS' product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).